biapenem
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01702649)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- D-alanyl-D-alanine carboxypeptidaseINHIBITOR
dac inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)[O-])=C(SC3Cn4cnc[n+]4C3)[C@H](C)[C@H]12- Mol. weight
- 350.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL285347 ↗
Also known as
- 3-((6,7-dihydro-5h-pyrazolo(1,2-a)(1,2,4)triazol-4-ium-6-yl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3,2,0)hept-2-ene-2-carboxylate
- 5h-pyrazolo(1,2-a)(1,2,4)triazol-4-ium, 6-((2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-en-3-yl)thio)-6,7-dihydro-, hydroxide, inner salt, (4r-(4alpha,5beta,6beta(r*)))-
- biapenem
- biapenem
- biapenem
- biapenem
- biapenem
- biapenem
- biapenem
- biapenem
- biapenern
- cl-186815
- cl-186815
- cl-186815
- cli 86815
- cli 86,815
- cli-86815
- l 627
- l-627
- l-627
- l-627
- l-627
- lj-c10627
- lj-c10627
- ljc 10627
- ljc-10627
- ljc-10627
- ljc10,627
- omegacin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01772836 | Phase 1 | Mar 1, 2013 | Sponsor GmbH, The Medicines Company |
| NCT01702649 | Phase 1 | Aug 1, 2012 | Sponsor GmbH, The Medicines Company |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sponsor GmbH | Academic/Hospital | 2 | 0 | 1 | 2012 |
| The Medicines Company | For profit | 2 | 2 | 1 | 2012 |
2 organizations
Page 1 / 1